Eligibility Metastatic Breast Cancer NCT01935102

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis histologically confirmed of metastatic breast cancer
Beschreibung

ID.1

Datentyp

boolean

age (from 18 to 90 years)
Beschreibung

ID.2

Datentyp

boolean

eastern cooperative oncology group (ecog) performance status (0 or 1-2)
Beschreibung

ID.3

Datentyp

boolean

hormonal-receptor status (positive or negative)
Beschreibung

ID.4

Datentyp

boolean

previous adjuvant chemotherapy (none, anthracycline or anthracycline plus taxane)
Beschreibung

ID.5

Datentyp

boolean

previous hormonal therapy (adjuvant or metastatic)disease-free interval from the first diagnosis of breast cancer (≤ or >12 months)
Beschreibung

ID.6

Datentyp

boolean

extent of disease (≤ or >3 sites)
Beschreibung

ID.7

Datentyp

boolean

location of disease (viscera or bone)
Beschreibung

ID.8

Datentyp

boolean

disease evaluation (measurable or non-measurable)and bevacizumab maintenance (yes or no).
Beschreibung

ID.9

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with human epidermal growth factor receptor type 2 (her2)-positive
Beschreibung

ID.10

Datentyp

boolean

Ähnliche Modelle

Eligibility Metastatic Breast Cancer NCT01935102

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
diagnosis histologically confirmed of metastatic breast cancer
boolean
ID.2
Item
age (from 18 to 90 years)
boolean
ID.3
Item
eastern cooperative oncology group (ecog) performance status (0 or 1-2)
boolean
ID.4
Item
hormonal-receptor status (positive or negative)
boolean
ID.5
Item
previous adjuvant chemotherapy (none, anthracycline or anthracycline plus taxane)
boolean
ID.6
Item
previous hormonal therapy (adjuvant or metastatic)disease-free interval from the first diagnosis of breast cancer (≤ or >12 months)
boolean
ID.7
Item
extent of disease (≤ or >3 sites)
boolean
ID.8
Item
location of disease (viscera or bone)
boolean
ID.9
Item
disease evaluation (measurable or non-measurable)and bevacizumab maintenance (yes or no).
boolean
Item Group
C0680251 (UMLS CUI)
ID.10
Item
patients with human epidermal growth factor receptor type 2 (her2)-positive
boolean